Acetyl Hexapeptide-38
Ac-SVVVRT, a cosmetic peptide sold for local volume. Its one human report is a single case in which it was one of three injected agents.
Acetyl hexapeptide-38 is a synthetic hexapeptide, Ac-Ser-Val-Val-Val-Arg-Thr (PubChem lists it under its INCI name and the trade name Adifyline). It is sold for cosmetic volumising products. The only paper on PubMed that names it is a 2026 case report of chronic facial paralysis treated with a fat-restructuring procedure plus DMAE, organic silicon and the peptide, so its own effect is untested. It is not a drug.
No dosing data yet Details ↓
Recommended Dosing
No dosing data yet
This page has no dosing data yet.
Mechanism of action
Not established: no published study describes its action.
Primary uses
- Cosmetic skin-care formulations
Typical dosing
No published study states an amount of this ingredient used on skin, and a supplier's use level is not a source on this site, so none is given.
Regulatory status
Not a drug: PubChem lists it under its INCI name as a cosmetic ingredient (CID 155886972). Drugs@FDA and the EMA medicines list hold no record for it (searched October 28, 2026).
Status as of this entry's last review, October 28, 2026. Approvals, compounding rules and sport rules change; the regulatory tracker is checked more often.
What we checked
Acetyl Hexapeptide-38 is a cosmetic peptide ingredient with little or no published literature; this section records what can be checked.
Identity, computed
| Sequence | Ac-Ser-Val-Val-Val-Arg-Thr (Ac-SVVVRT) |
| Formula | C30H55N9O10 |
| Average mass | 701.82 g/mol |
| Monoisotopic mass | 701.4072 Da |
| Isoelectric point | 8.05 (net charge +0.0 at pH 7) |
The sequence is the one PubChem's record gives (Ac-Ser-Val-Val-Val-Arg-Thr, free acid; the record does not state stereochemistry); the values below are computed and agree with PubChem's formula.
Regulatory status, read October 28, 2026
Drugs@FDA: 0 records for “acetyl hexapeptide-38”. EMA medicines list: 0 records for “acetyl hexapeptide-38”. Run for semaglutide, the same queries return 6 and 5 records (and the registry search 80 trials), so a zero here is an absence, not a broken search. Not named on the WADA 2026 and 2027 Prohibited Lists. As a substance with no current approval for human therapeutic use, it falls under section S0 (non-approved substances), which is prohibited at all times; the lists were read on October 28, 2026.
What the studies show
A 2026 case report treated chronic peripheral facial paralysis with cannula-based fat restructuring combined with DMAE, organic silicon and acetyl hexapeptide-38 (Calfin et al., 2026). One patient and three agents: nothing can be attributed to the peptide.
What we looked for and did not find
No controlled study of the peptide in people, no registry record and no drug approval.
| Source | Query | Results, October 28, 2026 | What it was |
|---|---|---|---|
| PubMed | ("hexapeptide-38"[tiab] OR "hexapeptide 38"[tiab]) AND acetyl[tiab] OR adifyline[tiab] | 1 | the hyphenated INCI name is matched word by word (Q958): a phrase search for a hyphen-numbered name misses papers |
| ClinicalTrials.gov | acetyl hexapeptide-38 | 0 | |
| Drugs@FDA (openFDA) | acetyl hexapeptide-38 | 0 | |
| EMA medicines list | acetyl hexapeptide-38 | 0 |
References
- [other] PubChem CID 155886972, Acetyl Hexapeptide-38: formula C30H55N9O10, molecular weight 701.8. Read October 28, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/155886972
- [case-report] Calfin H, et al. "Facial Adipostructuring With Biochemical Modulation in Chronic Peripheral Facial Paralysis: A Case Report." Cureus, 2026;18(6):e111350. PMID: 42344748.
Related peptides
Guides & tools
Explore with tools
This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.